Significance of the microbiome in obstructive lung disease
- PMID: 22318161
- PMCID: PMC3578398
- DOI: 10.1136/thoraxjnl-2011-201183
Significance of the microbiome in obstructive lung disease
Abstract
The composition of the lung microbiome contributes to both health and disease, including obstructive lung disease. Because it has been estimated that over 70% of the bacterial species on body surfaces cannot be cultured by currently available techniques, traditional culture techniques are no longer the gold standard for microbial investigation. Advanced techniques that identify bacterial sequences, including the 16S ribosomal RNA gene, have provided new insights into the depth and breadth of microbiota present both in the diseased and normal lung. In asthma, the composition of the microbiome of the lung and gut during early childhood development may play a key role in the development of asthma, while specific airway microbiota are associated with chronic asthma in adults. Early bacterial stimulation appears to reduce asthma susceptibility by helping the immune system develop lifelong tolerance to innocuous antigens. By contrast, perturbations in the microbiome from antibiotic use may increase the risk for asthma development. In chronic obstructive pulmonary disease, bacterial colonisation has been associated with a chronic bronchitic phenotype, increased risk of exacerbations, and accelerated loss of lung function. In cystic fibrosis, studies utilising culture-independent methods have identified associations between decreased bacterial community diversity and reduced lung function; colonisation with Pseudomonas aeruginosa has been associated with the presence of certain CFTR mutations. Genomic analysis of the lung microbiome is a young field, but has the potential to define the relationship between lung microbiome composition and disease course. Whether we can manipulate bacterial communities to improve clinical outcomes remains to be seen.
Conflict of interest statement
Figures
References
-
- Hayashi H, Sakamoto M, Benno Y. Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods. Microbiol Immunol. 2002;46:535–48. - PubMed
Publication types
MeSH terms
Grants and funding
- U19 AI090871/AI/NIAID NIH HHS/United States
- G1000758/MRC_/Medical Research Council/United Kingdom
- U01 AI075410/AI/NIAID NIH HHS/United States
- K23 HL093351/HL/NHLBI NIH HHS/United States
- UL1RR024986/RR/NCRR NIH HHS/United States
- RC1 HL100809/HL/NHLBI NIH HHS/United States
- U01 HL098961/HL/NHLBI NIH HHS/United States
- 1K23HL105572-01/HL/NHLBI NIH HHS/United States
- R01-AI064479/AI/NIAID NIH HHS/United States
- R21 AI087869/AI/NIAID NIH HHS/United States
- R21AT004732/AT/NCCIH NIH HHS/United States
- UL1 RR024986/RR/NCRR NIH HHS/United States
- AI075410/AI/NIAID NIH HHS/United States
- R21-AI083473/AI/NIAID NIH HHS/United States
- U01HL098964/HL/NHLBI NIH HHS/United States
- P30-DK034933/DK/NIDDK NIH HHS/United States
- R01 AI064479/AI/NIAID NIH HHS/United States
- K23 HL105572/HL/NHLBI NIH HHS/United States
- R01 DK070875/DK/NIDDK NIH HHS/United States
- R01 HL082480/HL/NHLBI NIH HHS/United States
- UH3 DK083993/DK/NIDDK NIH HHS/United States
- R21 AT004732/AT/NCCIH NIH HHS/United States
- U01 HL098964/HL/NHLBI NIH HHS/United States
- HHSN268200900016C/HL/NHLBI NIH HHS/United States
- AI113916/AI/NIAID NIH HHS/United States
- 097117/WT_/Wellcome Trust/United Kingdom
- R21-AI087869/AI/NIAID NIH HHS/United States
- R21 AI113916/AI/NIAID NIH HHS/United States
- P30 DK034933/DK/NIDDK NIH HHS/United States
- R21 AI083473/AI/NIAID NIH HHS/United States
- 1RC1HL100809-01/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical